Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Int Med Case Rep J
PMID 35359351
Who should not take GLP-1s GLP-1s in all forms are unsuitable for people who: are pregnant or breastfeeding do not meet the eligibility criteria have a family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) Medical Perspective Patients with needle phobia, a preference for pill-based routines, or good adherence to oral administration guidelines may be better suited to oral GLP-1 formulations like semaglutide (Rybelsus, Wegovy), which can enhance treatment acceptance and potentially offer strong glycemic or weight control
AUD: alcohol use disorder
Zinc transporter ZIP13 G289R variant from spondylocheirodysplastic EhlersDanlos syndrome (SCD-EDS) is associated with abnormal hair quality
Conclusions This real-world health economic evaluation along with a comprehensive systematic review suggest that the use of a GLP-1RA versus insulin has a high likelihood of being cost-effective for T2D patients who require intensified injection therapy from a third-party payer, healthcare sector, and societal perspectives
